Docoh
Loading...
Sign up Log in

NYMX Nymox Pharmaceutical

Nymox Pharmaceutical Corp. operates as a biopharmaceutical company, which engages in the research and development on products for the aging population. Its products include NicAlert and TobacAlert, and the NX-1207 for the treatment of low-grade localized prostate cancer. It operates through the following geographical segments: Canada, United States, and Europe. The company was founded by Paul Averback on May 30, 1995 and is headquartered in Nassau, the Bahamas.

Company profile

Ticker
NYMX
Exchange
NASDAQ
Website
www.nymox.com
CEO
Paul Averback
Employees
Location
Quebec, Canada
Fiscal year end
Dec 31
Sector
Manufacturing > Pharmaceutical Preparation Manufacturing
Industry (SIC)
In Vitro & In Vivo Diagnostic Substances
Idexx Laboratories • Myriad Genetics • Lantheus • Quidel • Neogen • Meridian Bioscience • Celldex Therapeutics • Oxford Immunotec Global • Achieve Life Sciences • Intellia Therapeutics ...
SEC CIK
0001018735
Corporate docs

NYMX stock data

(
)

News

Pro users get this 30m faster
Nymox Shares Spike To Session High Following Circulation Of European Patent Office Application For Co.'s 'NX-1207 FOR USE IN METHODS OF REDUCING THE NEED FOR SURGERY IN PATIENTS SUFFERING FROM BENIGN PROSTATIC HYPERPLASIA'
15 Mar 21
https://twitter.com/PatentGrants/status/1371536979268005890
95 Biggest Movers From Yesterday
5 Feb 21
Gainers ATA Creativity Global (NASDAQ: AACG) shares jumped 936.2% to close at $14.30 on Thursday thanks to discussions on Reddit investor forums WallStreetBets, Stocktwits, and Twitter’s platform, related to pumping the stock.
Nymox Pharma Shares Spike To Session High On Volume, Up 10.3%, Following Circulation Of World Intellectual Property Organization IP Portal Specifications For 'FOCAL TREATMENT OF PROSTATE CANCER'
4 Feb 21
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2021022005&PN=12970

Press releases

Pro users get this 30m faster
Nymox Provides New Update on Regulatory Activities
29 Mar 21
HASBROUCK HEIGHTS, N.J., March 29, 2021 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to provide the latest update on the Company's regulatory filing preparation activities. The

Calendar

29 Mar 21
13 Apr 21
31 Dec 21

Financial summary

Financial statements Chart NYMX financial data
Quarter (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
 Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Institutional ownership Q3 2019

NYMX institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
 Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
 Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Largest transactions
 Shares Bought/sold Change
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

?
Competition
Quest Diagnostics • Orasure
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. sophomore Avg
New words: accuracy, Addressing, andthe, Augusta, besufficient, CFY, comfort, Conceptual, derecognition, disruption, downstream, draft, essential, exact, fashion, Fulfilling, fundamental, goodwill, interpretation, Inventory, investee, irrespective, mentioned, pandemic, parent, slowdown, TPS, travel, unconsolidated, understood, USD
Removed: accreted, accretion, annum, approximate, Atlanta, bid, calculation, calendar, characterized, closing, confirmed, deficient, department, estimating, implicit, lessor, lien, matured, notification, occurrence, proportion, regain, regained, subscription
From filing 20-F 2020 FY

Financial reports

View all
20-F
2020 FY
Annual report (foreign)
29 Mar 21
20-F
2019 FY
Annual report (foreign)
30 Mar 20
20-F
2018 FY
Annual report (foreign)
29 Mar 19
20-F/A
2017 FY
Annual report (foreign) (amended)
11 May 18
20-F
2017 FY
Annual report (foreign)
29 Mar 18
20-F
2016 FY
Annual report (foreign)
30 Mar 17
20-F
2015 FY
Annual report (foreign)
30 Mar 16
20-F
2014 FY
Annual report (foreign)
30 Mar 15
20-F
2013 FY
Annual report (foreign)
13 Mar 14
20-F
2012 FY
Annual report (foreign)
14 Mar 13

Current reports

View all
6-K
Notice of the Annual General Meeting of the Shareholders
20 Nov 20
6-K
Current report (foreign)
19 Nov 20
6-K
2020 Q3
Current report (foreign)
13 Nov 20
6-K
Current report (foreign)
13 Oct 20
6-K
Nymox Announces Closing of $9 Million Registered Direct Offering
14 Aug 20
6-K
Current report (foreign)
14 Aug 20
6-K
Current report (foreign)
12 Aug 20
6-K
Nymox Announces $9 Million Registered Direct Offering
12 Aug 20
6-K
Current report (foreign)
20 Jul 20
6-K
2020 Q1
Current report (foreign)
14 May 20

Registration and prospectus

View all
424B5
Prospectus supplement for primary offering
14 Aug 20
424B5
Prospectus supplement for primary offering
13 Aug 20
424B5
Prospectus supplement for primary offering
17 Jul 20
F-3
Shelf registration (foreign)
3 Apr 20
424B5
Prospectus supplement for primary offering
8 Feb 16
F-3
Shelf registration (foreign)
13 Jul 15
424B3
Prospectus supplement
23 Mar 03
POS AM
Prospectus update (post-effective amendment)
11 Mar 03
POS AM
Prospectus update (post-effective amendment)
29 Jul 02
F-3
Shelf registration (foreign)
31 Mar 02

Proxies

No filings

Other

View all
EFFECT
Notice of effectiveness
13 May 20
CORRESP
Correspondence with SEC
6 May 20
UPLOAD
Letter from SEC
9 Apr 20
UPLOAD
Letter from SEC
20 Nov 16
CORRESP
Correspondence with SEC
14 Nov 16
UPLOAD
Letter from SEC
31 Oct 16
UPLOAD
Letter from SEC
20 Sep 16
CORRESP
Correspondence with SEC
3 Aug 15
EFFECT
Notice of effectiveness
3 Aug 15
UPLOAD
Letter from SEC
23 Jul 15

Ownership

View all
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
12 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
10 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
9 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
3 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
2 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
1 Jul 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
28 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
27 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
26 Jun 19
4
NYMOX PHARMACEUTICAL / James George Robinson ownership change
21 Jun 19

Patents

View all
APP
Utility
Focal Treatment of Prostate Cancer
4 Feb 21
The embodiments include methods of treating prostate cancer by administering to a low grade unifocal prostate cancer tumor a composition comprising a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of a low grade unifocal prostate cancer tumor, wherein administration reduces cancer incidence, cancer grade, and cancer progression (worsening) in the entire hemi-prostate where the initial focus was located and treated.
APP
Utility
Methods of Treating Multifocal Cancer
4 Feb 21
The embodiments include methods of treating (preventing or reducing the incidence of) multifocal cancer by administering to a unifocal cancer focus a composition comprising a therapeutically effective amount of a therapeutically effective amount of pharmaceutically active ingredient capable of inducing necrosis of the unifocal cancer tumor, wherein administration reduces multifocal cancer incidence, multifocal cancer grade, and multifocal cancer progression (worsening) in the entire organ or organism.
APP
Utility
Method of Enhancing the Therapeutic Efficacy of Fexapotide Triflutate In Treating Luts
18 Nov 20
Disclosed are methods of enhancing the therapeutic efficacy of Fexapotide Triflutate (TF) in treating LUTS, both irritative and obstructive, that include administering a composition comprising FT at least twice over a period spanning more than one year.
APP
Utility
Method of Treating Lower Urinary Tract Symptoms with Fexapotide Triflutate
18 Nov 20
Disclosed are methods of treating symptoms of Lower Urinary Tract Symptoms (LUTS), both obstructive and irritative, that include identifying patients having benign prostatic hyperplasia (BPH), and who also have LUTS, and administering a composition comprising FT to the so-identified patient.
APP
Utility
Method of Improving Lower Urinary Tract Symptoms
18 Nov 20
The embodiments include methods of improving the symptoms of mammals having LUTS, using compositions containing Fexapotide Triflutate and a pharmaceutically acceptable carrier.

Reddit threads

Pro users get this 30m faster